Dr Reddys Laboratories Ltd (DRREDDY)
₹1,151.70
Mkt cap
₹96,130 Cr
P/E ratio
29.80
P/B
2.54
Div yield
0.69%
ROE
11.20%
ROCE
13.00%
EPS (TTM)
₹38.65
Book value
₹454
52W range
1,152–1,376
Sector
Healthcare
Dr. Reddy's Laboratories Ltd is a leading India-based pharmaceutical company which offers a portfolio of products and services, including Active Pharmaceutical Ingredients (APIs), Custom Pharmaceutical services (CPS), generics, biosimilars and differentiated formulations.
Health check
Mixed
ValuationFair
ProfitabilityAverage
GrowthModerate
TechnicalsNeutral
52-week range
−16.28% from high₹1,152
₹1,1520.00% from low₹1,376
Current
₹1,151.70
Prev close
₹1,153.00
Day
−0.11%
Price performance
1D
−0.11%
1W
−5.84%
1M
−14.72%
3M
−12.56%
6M
−1.29%
1Y
−8.82%
YTD
−8.31%
Financials
FRevenue, profit & margin
P/E ratio
29.8×
DRREDDY is 12% below the sector median of 33.9×
DRREDDY29.8×
Sector median33.9×
| Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Jun 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 6,758 | 6,903 | 7,237 | 7,114 | 7,696 | 8,038 | 8,381 | 8,528 | 8,572 | 8,828 | 8,753 | 7,546 | 8,100 | |
| Expenses | 4,696 | 4,894 | 5,214 | 5,283 | 5,566 | 5,962 | 6,108 | 6,530 | 6,398 | 6,818 | 6,866 | 7,164 | 7,240 | |
| Operating Profit | 2,062 | 2,008 | 2,023 | 1,831 | 2,130 | 2,076 | 2,273 | 1,998 | 2,174 | 2,010 | 1,888 | 382 | 860 | |
| OPM % | 31% | 29% | 28% | 26% | 28% | 26% | 27% | 23% | 25% | 23% | 22% | 5% | 11% | |
| Other Income | 178 | 319 | 219 | 201 | 193 | 314 | 154 | 528 | 290 | 330 | 271 | 480 | 356 | |
| Interest | 37 | 35 | 39 | 59 | 60 | 76 | 82 | 66 | 83 | 91 | 94 | 106 | 126 | |
| Depreciation | 353 | 376 | 374 | 368 | 381 | 397 | 471 | 455 | 476 | 505 | 521 | 557 | 537 | |
| Profit before tax | 1,850 | 1,917 | 1,829 | 1,605 | 1,883 | 1,917 | 1,874 | 2,005 | 1,905 | 1,745 | 1,543 | 200 | 553 | |
| Tax % | 24% | 23% | 24% | 18% | 26% | 30% | 25% | 21% | 26% | 23% | 23% | -11% | 21% | |
| Net Profit | 1,405 | 1,482 | 1,381 | 1,310 | 1,392 | 1,342 | 1,404 | 1,587 | 1,410 | 1,337 | 1,190 | 221 | 436 | |
| EPS in Rs | 16.87 | 17.77 | 16.56 | 15.70 | 16.69 | 15.05 | 16.94 | 19.09 | 16.99 | 16.14 | 14.50 | 2.65 | 5.32 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move +0.12% · closed higher next day 31 of last 60
| Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | Q1FY27 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 27 Oct '23◦ | 30 Jan '24◦ | 7 May '24◦ | 27 Jul '24◦ | 5 Nov '24◦ | 24 Jan '25 | 9 May '25◦ | 23 Jul '25◦ | 24 Oct '25◦ | 21 Jan '26◦ | 12 May '26◦ | 22 Jul '26◦ |
| Earnings day | −0.96% | +4.80% | −3.22% | −0.56% | +2.35% | −5.04% | +3.43% | +1.45% | +0.05% | +5.21% | −0.37% | −1.39% |
| +1 day | −0.55% | +2.61% | −6.08% | −1.08% | +1.19% | −7.12% | +4.43% | +2.45% | +0.45% | +6.77% | +2.65% | −2.52% |
| +5 days | −1.10% | +5.80% | −6.11% | −0.97% | −2.14% | −5.59% | +5.46% | +1.84% | −6.82% | +5.26% | +4.09% | — |
| +15 days | +4.62% | +8.70% | −4.10% | +1.26% | −5.49% | −5.10% | +7.94% | +1.04% | −3.10% | +9.58% | −0.20% | — |
| +30 days | +3.73% | +7.77% | −4.58% | −3.32% | +5.62% | −12.11% | +14.02% | +0.26% | −2.91% | +11.22% | +6.34% | — |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 8 Per Share | 8.00 | 10 Jul '26 | 10 Jul '26 |
Results analysis
Shareholding
Sas of Jun 202626.63%Promoter
Promoters26.63%
FIIs20.67%0.47
DIIs31.75%1.03
Public20.76%0.51
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,723 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.10 | 1,88,697 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,401 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,559 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Dr Reddy's Labs | ₹1,151.70 | 29.83 | 96,130 | 0.69% | 436 | −68.67% | 8,100 | −5.51% | 13.04% |
| Median: 157 Co. | ₹432.05 | 33.93 | 1,970 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2026bseFinancial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013nseFinancial Year 2013bse
Concall transcripts47
TranscriptJul 2026PPTJul 2026RECJul 2026RECJul 2026TranscriptMay 2026PPTMay 2026PPTMay 2026TranscriptJan 2026PPTJan 2026RECJan 2026TranscriptOct 2025PPTOct 2025RECOct 2025TranscriptJul 2025PPTJul 2025RECJul 2025TranscriptMay 2025RECMay 2025TranscriptJan 2025RECJan 2025TranscriptNov 2024RECNov 2024TranscriptAug 2024TranscriptJul 2024
Credit ratings6
Announcements5
Shareholder Meeting / Postal Ballot-Outcome of AGM 22h - Dr. Reddy’s 42nd AGM passed all resolutions, including Rs. 8 final dividend and director/auditor reappointments.Shareholder Meeting / Postal Ballot-Scrutinizer''s Report 22h - Dr. Reddy’s 42nd AGM approved FY26 results, Rs. 8 final dividend, and director/auditor reappointments.Announcement under Regulation 30 (LODR)-Change in Management 22h - AGM approves Dr. K P Krishnan reappointment, Srikanth Velamakanni appointment, and Deloitte Haskins & Sells LLP as auditors.Announcement under Regulation 30 (LODR)-Newspaper Publication 22hAnnouncement under Regulation 30 (LODR)-Press Release / Media Release 1d - Audio recording of Q1 FY2027 earnings call held on July 22, 2026 shared.